Imagen de Portada
Código QR

Investigation of Hepatitis B Surface Antibody Levels in Adults with Routine Hepatitis B Vaccination in Childhood.

Objectives: Recombinant hepatitis B vaccines provide effective and long-term protection. It is not well known whether it reaches protective levels of antibodies in adulthood. In this study, it was aimed to investigate hepatitis B surface antibody (anti-HBs) levels in adults who received routine hepa...

Descripción completa

Publicado en:Viral Hepatitis Journal / Viral Hepatit Dergisi Vol. 29; no. 2; pp. 70 - 75
Autores principales: Sehmen, Emine, Yılmaz, Esmeray Mutlu, Oruç, Muhammet Ali
Formato: research tables/charts Journal Article
Publicado: Galenos Yayinevi Tic. LTD. STI Aug2023
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=172322544&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 172322544
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        13079441
        FSWQ
      jtl: Viral Hepatitis Journal / Viral Hepatit Dergisi
      issn: 13079441
      maglogo: N
    pubinfo:
      dt: Aug2023
      vid: 29
      iid: 2
      pid: 28155
      pub: Galenos Yayinevi Tic. LTD. STI
    artinfo:
      ui:
        172322544
        172322544
        172322544
        10.4274/vhd.galenos.2023.2023-4-6
        172322544
      ppf: 70
      ppct: 5
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Investigation of Hepatitis B Surface Antibody Levels in Adults with Routine Hepatitis B Vaccination in Childhood.
      aug:
        au:
          Sehmen, Emine
          Yılmaz, Esmeray Mutlu
          Oruç, Muhammet Ali
        affil: Samsun Gazi State Hospital, Clinic of Infectious Diseases and Clinical Microbiology, Samsun, Turkey
      sug:
        subj:
          Antigens, Surface Blood
          Hepatitis B Prevention and Control
          Hepatitis B Vaccines Administration and Dosage
          Immunization
          Antibodies, Viral Blood
          Human
          Child
          Adult
          Age Factors
          Descriptive Statistics
          Child: 6-12 years
          Adult: 19-44 years
      ab:
        Objectives: Recombinant hepatitis B vaccines provide effective and long-term protection. It is not well known whether it reaches protective levels of antibodies in adulthood. In this study, it was aimed to investigate hepatitis B surface antibody (anti-HBs) levels in adults who received routine hepatitis B vaccination in the newborn period and to reveal its change with age. Materials and Methods: The hepatitis B surface antigen (HBsAg) and anti-HBs levels of those who applied to our hospital's health board between 01.01.2017 and 31.12.2021 and were at least 18 years old were evaluated by retrospectively scanned from the board records. Those with anti-HB titers above 10 mIU/mL were considered to have a protective antibody level. Results: The mean age was 20.0±1.5 (18-24). Anti-HBs result was found to be above 10 IU in 1,691 (70.8%) of 2,395 people who were HBsAg negative. In the study, the rate of those who were found to be anti-HBs negative at the age of 18 and 19 was significantly higher than the older age groups, and those with more than 1000 mIU/mL in the 23 and 24 age groups compared to the younger age groups (p<0.001). A significant correlation was found between age and anti-HBs levels (p<0.001; r=0.219). Conclusion: Our study is one of the rare studies measuring the level of hepatitis B vaccine protection for up to 24 years. Our findings demonstrated that the antibody level was found to be above 10 IU in 71% of adults included in the routine hepatitis B vaccination program after birth, and the antibody level did not decrease but rather increased with increasing age.
        Amaç: Rekombinant hepatit B aşıları etkili ve uzun süreli koruyuculuk sağlamaktadır. Erişkin çağda rutin olarak koruyucu düzeyde antikor seviyelerine ulaşıp ulaşmadığı iyi bilinmemektedir. Bu çalışmada, ülkemizde yenidoğan döneminde rutin hepatit B aşılaması yapılan yetişkinlerde hepatit B yüzey antikoru (anti-HBs) düzeylerinin ve bu düzeylerin yaşla ilişkisinin araştırılması amaçlanmıştır. Gereç ve Yöntemler: Hastanemiz sağlık kuruluna 01.01.2017-31.12.2021 tarihleri arasında başvuran ve en az 18 yaşında olanların hepatit B yüzey antijeni (HBsAg) ve anti-HBs düzeyleri kurul kayıtlarından geriye doğru taranarak değerlendirilmiştir. Anti-HBs titreleri 10 mIU/mL'nin üzerinde olanlar koruyucu antikor düzeyine sahip kabul edilmiştir. Bulgular: Ortalama yaşı 20,0±1,5 (18-24) idi. HBsAg negatif olan 2.395 kişinin 1.691'inin (%70,8) anti-HBs sonucunun 10 IU'nin üzerinde bulundu. Çalışmada 18 ve 19 yaşında olanlarda anti-HBs negatif saptananların oranı daha büyük yaş gruplarına göre, 23 ve 24 yaş gruplarında >1000 mIU/mL olanların olanı daha küçük yaş gruplarına göre anlamlı yüksekti (p<0,001). Yaş ve anti-HBs düzeyleri arasında anlamlı korelasyon saptandı (p<0,001; r=0,219). Sonuç: Çalışmamız 24 yıla varan hepatit B aşı koruyuculuğu düzeyini ölçen nadir çalışmalardandır. Bulgularımız doğumdan sonra rutin hepatit B aşılama programına dahil olan erişkinlerin %71'inde antikor seviyesinin 10 IU'nun üzerinde saptandığı, yaş artıkça antikor düzeyinin azalmadığı aksine artığını göstermiştir.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N